A vaccine delivery method is presented that includes a composition including as one component a slurry matrix that is a liquid at room temperature and a gel at physiological pH, physiological salt concentrations and/or physiological temperatures and as a second component one or more antigens. Also included are methods of inducing an immune response in a subject and vaccinating a subject by administering such compositions.

A vaccine delivery method is presented that includes a composition including as one component a slurry matrix that is a liquid at room temperature and a gel at physiological pH, physiological salt concentrations and/or physiological temperatures and as a second component one or more antigens. Also included are methods of inducing an immune response in a subject and vaccinating a subject by administering such compositions.

The present invention discloses novel recombinant multivalent non-pathogenic Marek's Disease virus constructs that encode and express foreign antigens from three or more avian viruses, along with methods of the use of the multivalent poultry virus vaccines.

The present invention discloses novel recombinant multivalent non-pathogenic Marek's Disease virus constructs that encode and express foreign antigens from three or more avian viruses, along with methods of the use of the multivalent poultry virus vaccines.

The present invention relates to novel stable compressed vaccine composition comprising at least one anhydrous antigenic component comprising a stabilizer susceptible to foaming when the composition is mixed with liquid diluent; and an effective amount of a sugar alcohol.

The present invention relates to novel stable compressed vaccine composition comprising at least one anhydrous antigenic component comprising a stabilizer susceptible to foaming when the composition is mixed with liquid diluent; and an effective amount of a sugar alcohol.

Provided herein is a non-natural isolated chicken fibroblast cell that has the characteristics of immortalized growth and supporting replication of Marek's Disease Virus (MDV), wherein number of MDV produced by the cell is at least 1.5-fold greater than the number of the same MDV produced by a DF-1 cell under the same conditions. Also provided herein are methods including producing virus using the cell, determining the number of virus in a sample using the cell, and using the cell to produce protein.

Provided herein is a non-natural isolated chicken fibroblast cell that has the characteristics of immortalized growth and supporting replication of Marek's Disease Virus (MDV), wherein number of MDV produced by the cell is at least 1.5-fold greater than the number of the same MDV produced by a DF-1 cell under the same conditions. Also provided herein are methods including producing virus using the cell, determining the number of virus in a sample using the cell, and using the cell to produce protein.

The invention relates to a recombinant Gallid herpesvirus 3 vector encoding heterologous avian pathogen antigens comprising one or more heterologous polynucleotide(s) inserted into the intergenic loci UL3/UL4 and/or UL21/UL22. The invention further relates to vaccines comprising said recombinant Gallid herpesvirus 3 vector and optionally a further Marek's disease virus vector and to a use of the vaccine for protecting an avian species against one or more avian pathogens. Further methods for treating an avian species for protection against one or more diseases caused by avian pathogens and a method for producing the recombinant Gallid herpesvirus 3 vector encoding heterologous avian pathogen antigens is provided.

The invention relates to a recombinant Gallid herpesvirus 3 vector encoding heterologous avian pathogen antigens comprising one or more heterologous polynucleotide(s) inserted into the intergenic loci UL3/UL4 and/or UL21/UL22. The invention further relates to vaccines comprising said recombinant Gallid herpesvirus 3 vector and optionally a further Marek's disease virus vector and to a use of the vaccine for protecting an avian species against one or more avian pathogens. Further methods for treating an avian species for protection against one or more diseases caused by avian pathogens and a method for producing the recombinant Gallid herpesvirus 3 vector encoding heterologous avian pathogen antigens is provided.